Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human IL13RA2 /CD213 Protein, Fc Tag, 200µg  

Recombinant human IL13RA2 /CD213 Protein, Fc Tag, 200µg

Recombinant Human IL-13 R alpha 2 Protein, Asp 27 - Arg 343, produced in human 293 cells (HEK293), Fc Tag

Synonym
Recombinant Human Protein, IL13RA2, CD213A2, CD213α2, CT19, IL13BP, IL-13Rα2

More details

IL2-H5257-200

Availability: within 7 days

420,00 €

Background
Interleukin-13 receptor subunit alpha-2, also known as IL13Rα2, IL13Ra2 cluster of differentiation 213A2, CD213A2, CT19, IL-13R and IL13BP is a membrane bound protein that in humans is encoded by the IL13RA2 gene. IL13Rα2 is closely related to IL13Rα1, a subunit of the interleukin-13 receptor complex. This protein binds IL13 with high affinity, but lacks any significant cytoplasmic domain, and does not appear to function as a signal mediator. It is, however able to regulate the effects of both IL13 and IL4, despite the fact it is unable to bind directly to the latter. It is also reported to play a role in the internalization of IL13. IL13Rα2 is a component of the cell surface receptors, however, the majority exists in intracellular pools and in soluble form, and thus plays an opposite role as a potent IL13 antagonist compared with IL13Rα1. It also functions as an inhibitor of IL4-dependent pathway probably through the physical interaction between the short intracellular domain of and cytoplasmic domain of IL13Rα2 and the IL4Rα chain. In spite of the failed STAT signaling function, IL13Rα2 dose induce TGF-beta production and fibrosis. Additionally, IL13Rα2 has been reported to be abundantly and specifically overexpressed in glioblastoma multiforme.

Source
Receptor human IL-13 R alpha 2 Protein, Fc Tag (Human IL-13 R alpha 2, Fc Tag) Asp 27 - Arg 343 (Accession # NP_000631.1) was produced in human 293 cells (HEK293)

Molecular Characterization
Human IL-13 R alpha 2, Fc Tag is fused with a human IgG1 Fc tag at the C-terminus, and has a calculated MW of 63.2 kDa. The predicted N-terminus is Asp 27. The reducing (R) protein migrates as 80-90 kDa in SDS-PAGE due to glycosylation.

Endotoxin
Less than 1.0 EU per μg of the rhIL13Ra2-Fc by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM tris, 100 mM glycine, pH7.0. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
In lyophilized state for 1 year (4C-8C); After reconstitution under sterile conditions for 1 month (4C-8C) or 3 months (-20C to -70C).

References

(1) Daines, M.O. et al., 2006, J. Immunol. 176: 7495-7501.
(2) Fichtner-Feigl, S. et al., 2006, Nat. Med. 12: 99-106
(3) Rahaman, S.O. et al., 2002, Cancer. Res. 62: 1103-1109
(4) Okano, F. et al., 2002, Clin. Cancer. Res. 8: 2851-2855